cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2014-4-64-68cardiovascular-36Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMВОЗМОЖНОСТИ ПРАКТИЧЕСКОГО ВРАЧА В ПЕРВИЧНОЙ ПРОФИЛАКТИКЕ МОЗГОВОГО ИНСУЛЬТА. РОЛЬ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИTHE PRIMARY CARE PHYSICIAN ROLE IN PRIMARY STROKE PREVENTION. THE PLACE FOR ANTIHYPERTENSIVE THERAPYМарцевичС. Ю.MartsevichS. Yu.

руководитель отдела профилактической фармакотерапии

Тел.: +7 (499) 553–68–13; (495) 627–03–08

smartsevich@gnicpm.ruКутишенкоН. П.KutishenkoN. P.

руководитель лаборатории фармакоэпидемиологических исследований отдела

ФГБУ “Государственный научно-исследовательский центр профилактической медицины” Минздрава России, МоскваFSBI State Scientific-Research Centre for Preventive Medicine of the Ministry of Health, Moscow2014200820141346468Copyright © Марцевич С.Ю., Кутишенко Н.П., 20142014Марцевич С.Ю., Кутишенко Н.П.Martsevich S.Y., Kutishenko N.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/36

В статье приводится определение мозгового инсульта (МИ), данные о смертности от этого заболевания, факторы риска, способствующие его развитию. Детально анализируется роль антигипертензивной терапии в первичной профилактике МИ, значимость отдельных антигипертензивных препаратов с позиций доказательной медицины. 

The article provides the definition of stroke, data on the mortality, risk factors. In detail, the role of antihypertension therapy is analized for primary stroke prevention, the significance of various antihypertension drugs from the evidence based point of view. 

мозговой инсультпервичная лекарственная профилактикароль антигипертензивной терапиипроблема выбора препаратаbrain strokeprimary prophylaxythe role of antihypertension therapyproblem of drug choiceReferencesWarlow C, Sudlow C, Dennis M, et al. Stroke. Lancet 2003;362:1211–24.Warlow C, Sudlow C, Dennis M, et al. Stroke. Lancet 2003;362:1211–24.Go AS, Mozaffarian D, Roger V, et al. Heart Disease and Stroke Statistics-2014 Update: A Report From the American Heart Association. Circulation. published online December 18, 2013.Go AS, Mozaffarian D, Roger V, et al. Heart Disease and Stroke Statistics-2014 Update: A Report From the American Heart Association. Circulation. published online December 18, 2013.D’Agostinio RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertansive medication: the Framingham Study. Stroke 1994; 25: 40–3.D’Agostinio RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertansive medication: the Framingham Study. Stroke 1994; 25: 40–3.2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013. doi: 10.1093/eurheartj/eht151.2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013. doi: 10.1093/eurheartj/eht151.Camm J, Lip G, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J doi:10.1093/eurheartj/ ehs253.Camm J, Lip G, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J doi:10.1093/eurheartj/ ehs253.Perk J, De Backer G, Gohlke H, et al., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J doi:10.1093/eurheartj/ ehs092.Perk J, De Backer G, Gohlke H, et al., European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J doi:10.1093/eurheartj/ ehs092.Veterans Administration Co-operative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028–34.Veterans Administration Co-operative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028–34.Coope J, Warrender T. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986; 293: 1145–8.Coope J, Warrender T. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986; 293: 1145–8.MRC Working Party. Medical Research Council trial of hypertension in older adults: principal results. Br Med J 1992; 304: 405–12.MRC Working Party. Medical Research Council trial of hypertension in older adults: principal results. Br Med J 1992; 304: 405–12.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–35.SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64. 13. Staessen J, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with Isolated systolic hypertension in Europe. Lancet 1997; 350: 757–64.SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older patients with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64. 13. Staessen J, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with Isolated systolic hypertension in Europe. Lancet 1997; 350: 757–64.Liu L, Wang JG, Celis H, Staesen JA. Implications of Systolic Hypertension in China trial. Clin Exp Hypertens 1999; 21: 499–505.Liu L, Wang JG, Celis H, Staesen JA. Implications of Systolic Hypertension in China trial. Clin Exp Hypertens 1999; 21: 499–505.Liu L, Zhang Y, Liu G, et al.; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157–72.Liu L, Zhang Y, Liu G, et al.; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157–72.Beckett NS, Peters R, Fletcher AE, et al., Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358: 1887–98.Beckett NS, Peters R, Fletcher AE, et al., Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358: 1887–98.Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231–43.Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231–43.Boytsov SA, Martsevich SYu, Ginzburg, ML, et al. Lyubertsy study on mortality rate in patients after cerebral stroke or transient ischemic attack (LIS-2). Design and medical treatment estimation. Ration Pharmacother Cardiol 2013; 9 (2): 114–22. Russian (Бойцов С.А., Марцевич С.Ю., Гинзбург М.Л. и др. Люберецкое исследование смертности больных, перенесших мозговой инсульт или транзиторную ишемическую атаку (ЛИС-2). Дизайн и оценка лекарственной терапии. Рациональная фармакотерапия в кардиологии 2013; 9 (2): 114–22).Boytsov SA, Martsevich SYu, Ginzburg, ML, et al. Lyubertsy study on mortality rate in patients after cerebral stroke or transient ischemic attack (LIS-2). Design and medical treatment estimation. Ration Pharmacother Cardiol 2013; 9 (2): 114–22. Russian (Бойцов С.А., Марцевич С.Ю., Гинзбург М.Л. и др. Люберецкое исследование смертности больных, перенесших мозговой инсульт или транзиторную ишемическую атаку (ЛИС-2). Дизайн и оценка лекарственной терапии. Рациональная фармакотерапия в кардиологии 2013; 9 (2): 114–22).

The authors declare that there are no conflicts of interest present.